当前位置：
X-MOL 学术
›
Aliment. Pharm. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2021-10-20 , DOI: 10.1111/apt.16664 Rifaat Safadi 1 , Marius Braun 2 , Adi Francis 3 , Yael Milgrom 1 , Muhammad Massarwa 1 , David Hakimian 1 , Wadi Hazou 1 , Assaf Issachar 2 , Zivit Harpaz 4 , Motti Farbstein 4 , Inbal Itzhak 4 , Naama Lev-Cohain 5 , Avital Bareket-Samish 6 , Michael H Silverman 4 , Pnina Fishman 4
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2021-10-20 , DOI: 10.1111/apt.16664 Rifaat Safadi 1 , Marius Braun 2 , Adi Francis 3 , Yael Milgrom 1 , Muhammad Massarwa 1 , David Hakimian 1 , Wadi Hazou 1 , Assaf Issachar 2 , Zivit Harpaz 4 , Motti Farbstein 4 , Inbal Itzhak 4 , Naama Lev-Cohain 5 , Avital Bareket-Samish 6 , Michael H Silverman 4 , Pnina Fishman 4
Affiliation
|
Namodenoson, an A3 adenosine receptor (A3AR) agonist, improved liver function/pathology in non-alcoholic steatohepatitis (NASH) preclinical models.
中文翻译：
随机临床试验：萘莫德松治疗非酒精性脂肪肝和脂肪性肝炎的 2 期双盲研究
Namodenoson 是一种 A3 腺苷受体 (A3AR) 激动剂，可改善非酒精性脂肪性肝炎 (NASH) 临床前模型的肝功能/病理学。
更新日期：2021-11-07
中文翻译：
随机临床试验：萘莫德松治疗非酒精性脂肪肝和脂肪性肝炎的 2 期双盲研究
Namodenoson 是一种 A3 腺苷受体 (A3AR) 激动剂，可改善非酒精性脂肪性肝炎 (NASH) 临床前模型的肝功能/病理学。
京公网安备 11010802027423号